首页> 外国专利> Endosialin (CD248) as an epigenetic marker for the identification of immune cells, in particular naïver CD8 + T cells

Endosialin (CD248) as an epigenetic marker for the identification of immune cells, in particular naïver CD8 + T cells

机译:Endosialin(CD248)作为表观遗传学标志物,用于鉴定免疫细胞,特别是幼稚的CD8 + T细胞

摘要

The present invention relates to a method, in particular an in vitro method, for identifying specific immune cells, in particular naive CD8 + T cells, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for endosialin (CD248) Demethylation or lack of methylation of this gene region is indicative of a naive CD8 + T cell when compared to a non-naive CD8 + T cell or other (blood) cell type. Analyzes according to the invention can identify naive CD8 + T cells at the epigenetic level and differentiate them from all other cells in complex samples, such as other blood or immune cells. In addition, the present invention provides an improved method for quantifying naive CD8 + T cells, especially in complex samples. The method may be performed without a step of purifying and / or enriching the cells, preferably by using whole blood and / or non-trypsinized tissue.
机译:本发明涉及用于鉴定特异性免疫细胞,特别是幼稚CD8 + T细胞的方法,特别是体外方法,包括分析内皮唾液酸蛋白(CD248)在哺乳动物基因区域中至少一个CpG位置的甲基化状态。与非天然CD8 + T细胞或其他(血液)细胞类型相比,该基因区域的去甲基化或缺乏甲基化指示天然CD8 + T细胞。根据本发明的分析可以在表观遗传水平上鉴定幼稚的CD8 + T细胞,并将它们与复杂样品中的所有其他细胞,例如其他血液或免疫细胞区分开。另外,本发明提供了一种定量幼稚CD8 + T细胞的改进方法,特别是在复杂样品中。可以优选地通过使用全血和/或非胰蛋白酶化的组织而无需纯化和/或富集细胞的步骤来执行该方法。

著录项

  • 公开/公告号DE102017125150A1

    专利类型

  • 公开/公告日2019-05-02

    原文格式PDF

  • 申请/专利权人 EPIONTIS GMBH;

    申请/专利号DE201710125150

  • 发明设计人 SVEN OLEK;JANIKA JOSEPHIN SCHULZE;

    申请日2017-10-26

  • 分类号C12Q1/68;

  • 国家 DE

  • 入库时间 2022-08-21 11:45:19

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号